Pedro Barata discusses systemic therapy selection and monitoring in low-volume metachronous metastatic hormone-sensitive prostate cancer. He emphasizes that low disease volume doe ...
Catherine Marshall discusses fatigue, functional decline, and treatment burden in metastatic castrate-sensitive prostate cancer. Dr. Marshall frames fatigue not as a subjective co ...
Yudai Ishiyama presents a restricted mean survival time analysis of four IO combination regimens in advanced clear cell RCC. Using digitized Kaplan-Meier data from CheckMate 214, ...
Sara Khor presents a study linking pre-diagnosis financial hardship to late-stage cancer diagnosis, drawing on SEER, TransUnion credit report, and insurance claims data from appro ...
ASCO 2024 Bladder Cancer ASCO 2024: What Is Variant Histology Urothelial Cancer and What Are the Available Treatment Options? ASCO 2024: Phase II Trial of Intravesical Camrelizumab in BCG-Unresponsive ...
Cristina Suárez describes LITESPARK-033, a phase 3 trial addressing an unmet need in patients who progress during or within 24 months after adjuvant pembrolizumab for clear cell renal cell carcinoma.
Relationship Between the Frequency of Electrocautery of Hunner Lesions and Changes in Bladder Capacity in Patients with Hunner Type Interstitial Cystitis - Beyond the Abstract ...
Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
AUA 2026, BCG naive and BCG-Exposed High-Risk Non–muscle Invasive Bladder Cancer, Intravesical MK-3120, anti–Nectin-4 monoclonal antibody, MK-3120 I-VESIC.
(UroToday.com) The 2023 ASCO annual meeting included a kidney cancer session, featuring a presentation by Dr. Brian Rini discussing the 5-year analysis of KEYNOTE-426, assessing pembrolizumab + ...
SNMMI 2025: Development of PSMA Targeting Radioligand 161Tb-LNC1011 for Prostate Cancer Theranostics
(UroToday.com) The 2025 SNMMI annual meeting featured a radiotheranostics session and a presentation by Dr. Xuejen Wen discussing the development of PSMA targeting radioligand 161 Tb-LNC1011 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results